Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast
This study has been completed.
Sponsored by: M.D. Anderson Cancer Center
Information provided by: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00147238
  Purpose

Primary Objective:

1. To re-validate the accuracy of ferumoxtran-10, a new ultra-small superparamagnetic oxide (USPIO) particles, using currently available a high-resolution MR imaging technique in patients with surgically resectable carcinomas of prostate, penis, and urinary bladder in their initial staging work-ups.


Condition Intervention
Bladder Cancer
Genitourinary Cancer
Prostate Cancer
Drug: Ferumoxtran-10

Genetics Home Reference related topics: bladder cancer
MedlinePlus related topics: Bladder Cancer Cancer Prostate Cancer
Drug Information available for: Ferumoxtran-10
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

Further study details as provided by M.D. Anderson Cancer Center:

Estimated Enrollment: 80
Study Start Date: July 2005
Estimated Study Completion Date: January 2007
Detailed Description:

The contrast agent, ferumoxtran-10, is made of ultra small iron oxide particles. Once they are injected through vein, they are taken up mostly by liver, spleen, bone marrow, and lymph nodes. It takes about 24 - 36 hours to reach peak uptake in the lymph nodes. The ability of current imaging techniques to detect the lymph nodes disease is known to be less than perfect. Current techniques only use anatomic information (size). Previous studies have shown that this new contrast agent may be able to detect normal and abnormal lymph nodes, using MRI procedure, called MRI lymphangiogram. This new contrast agent is being evaluated to determine whether it can be used to detect normal and abnormal lymph nodes.

The study includes 2 parts. The first part will involve you receiving a MRI examination before the contrast is injected. The second part will involve you receiving a MRI examination about 24 hours after the injection. It will take about 20 minutes for each part.

If you are already scheduled to have a routine pelvic MRI, the first part of this study will be added at the end of the routine MRI. You will then be asked to return next day to complete the second part of the MRI. If you are not already scheduled to receive a MRI as part of your standard of care, you will come in to the MRI suite at M. D. Anderson and complete both parts over about a 24-hour interval.

You will be lying on the MRI examination table during the scanning. At the end of the first part of the study, the contrast will be infused slowly through vein over about 30 minutes in the recovery area. You will then be observed for 30 minutes to 2 hours, depending on your tolerance to the contrast agent. The images taken during the first part will be then be repeated 24-36 hours later. You will receive a follow-up telephone call from a member of the study staff on Day 3.

Once the second part of the MRI is performed, your participation in this study will be over.

This is an investigational study. This contrast agent is currently being evaluated by FDA and has not been approved yet. You will be charged for your routine MRI but not for the study MRIs. A total of 80 patients will take part in this study. All will be enrolled at M. D. Anderson.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with newly diagnosed pelvic urological tumors, including prostate carcinomas, bladder carcinomas, and penile carcinomas.
  2. Planned to have a surgical exploration or a laparoscopy for pelvic lymph node dissection/biopsy within 4 weeks.
  3. Signed written consent and HIPAA authorization

Exclusion Criteria:

  1. Contraindications for MRI
  2. Claustrophobia, metals in the pelvis, previous pelvic surgery
  3. Allergy or hypersensitivity to iron products, dextrans, iron-dextran complex
  4. a. Prostate cancer: metastases demonstrated on preoperative imaging; prior hormonal therapy greater than 3 months; prior local therapy for prostate cancer b. Penile Cancer: prior systemic therapy for penile cancer; prior inguinal radiation c. Bladder Cancer: prior systemic therapy for bladder cancer (does NOT include intravesical chemotherapy or immunotherapy); prior pelvic radiation; history of partial cystectomy or prior pelvic lymph node dissection
  5. Women of child-bearing potential. (Women who will be having hysterectomy as part of bladder surgery will not be excluded.)
  6. Clinically documented or risk of primary or secondary iron overloading (e.g.History of thalassemia, sickle cell anemia, hereditary hemochromatosis, multiple transfusions with any reason)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00147238

Locations
United States, Texas
U.T.M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Haesun Choi, MD U.T.M.D. Anderson Cancer Center
  More Information

Study ID Numbers: 2004-0003
Study First Received: September 6, 2005
Last Updated: March 9, 2007
ClinicalTrials.gov Identifier: NCT00147238  
Health Authority: United States: Food and Drug Administration;   United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Bladder Cancer
Genitourinary Cancer
Prostate Cancer
MR Lymphangiography
Ferumoxtran-10
SPIO

Study placed in the following topic categories:
Cystocele
Prostatic Diseases
Genital Neoplasms, Male
Urologic Diseases
Urinary Bladder Diseases
Urinary Bladder Neoplasms
Urogenital Neoplasms
Genital Diseases, Male
Urologic Neoplasms
Prostatic Neoplasms
Urinary tract neoplasm
Bladder neoplasm

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 16, 2009